AACR Urges FDA to Regulate High-Risk LDTs | GenomeWeb

NEW YORK (GenomeWeb) – The American Association for Cancer Research today urged the US Food and Drug Administration to start actively regulating "high risk" lab developed tests that doctors are using to make decisions about how to treat their cancer patients.

In addition, the association's immediate past president Charles Sawyers was scheduled to provide testimony in a hearing being held today by a House of Representatives committee to provide Congress with a better picture of how LDTs are being used and the regulatory structures that affect them.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.